







Ipamorelin
Ipamorelin from Super Human Peptides UK is a synthetic pentapeptide and a highly selective Growth Hormone-Releasing Peptide (GHRP). It acts as an agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R). In laboratory research, Ipamorelin is widely considered one of the most refined and "cleanest" secretagogues available.
Unlike earlier generation peptides such as GHRP-6 or Hexarelin, researchers utilize Ipamorelin because it stimulates a significant, pulsatile release of growth hormone without simultaneously elevating cortisol, acetylcholine, or prolactin levels. Produced under GMP-compliant conditions and verified for 99% purity or higher, Ipamorelin provides an ideal model for studying the somatotropic axis without the interference of stress-hormone cascades.
- —High Selectivity: Stimulates GH release without cortisol or prolactin spikes.
- —Maximum Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —No Appetite Stimulation: Does not induce the extreme hunger response often seen in other GHRPs.
- —Quality Standard: GMP / ISO certified manufacturing.
- —Selective GH Pulsatility: Measuring pituitary output without secondary stress-hormone interference.
- —Bone Mineral Density: Preclinical models investigating the peptide's ability to increase bone formation rates.
- —Lean Muscle Tissue Retention: Studies on nitrogen balance and protein synthesis during metabolic stress.
- —Gastric Motility: Researching its mild prokinetic effects on the gastrointestinal tract in animal models.
- —Gerontology and Anti-Aging: Exploring the restoration of natural GH pulses in aged animal models.
Ipamorelin was first detailed in scientific literature by Raun et al. (1998) as the first highly selective growth hormone secretagogue. Laboratory studies have consistently demonstrated that while its GH-releasing potency is similar to GHRP-6, its lack of effect on ACTH and cortisol makes it unique.
This allows researchers to study the pure physiological effects of elevated growth hormone—such as increased bone density and muscle tissue repair—without the confounding variables introduced by elevated stress hormones. Furthermore, long-term animal studies indicate that Ipamorelin does not cause rapid receptor desensitization (down-regulation) to the same extent as Hexarelin. This makes it a preferred peptide for prolonged, multi-week research models focusing on steady, consistent somatotropic stimulation.
- 1.Raun, K. et al., "Ipamorelin, the first selective growth hormone secretagogue," European Journal of Endocrinology, 1998.
- 2.Johansen, P.B. et al., "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats," Growth Hormone & IGF Research, 1999.
- 3.Svensson, J. et al., "The GH secretagogues Ipamorelin and GHRP-6 increase bone mineral content in adult female rats," Journal of Endocrinology, 2000.
- 4.Venkova, K. et al., "Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus," Journal of Pharmacology and Experimental Therapeutics, 2009.


